[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL INTERVENTIONAL ONCOLOGY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL INTERVENTIONAL ONCOLOGY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 EMBOLIZATION DEVICES
5.3 ABLATION DEVICES
5.4 SUPPORT DEVICES

6 GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE
6.1 OVERVIEW
6.2 LIVER CANCER 
6.3 LUNG CANCER
6.4 BREAST CANCER
6.5 PROSTATE CANCER
6.6 KIDNEY CANCER
6.7 BONE METASTASIS
6.8 OTHER CANCERS

7 GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY END-USER
7.1 OVERVIEW
7.2 HOSPITALS
7.3 AMBULATORY SURGERY CENTERS
7.4 RESEARCH AND ACADEMIC INSTITUTES
7.5 OTHERS

8 GLOBAL INTERVENTIONAL ONCOLOGY MARKET, BY GEOGRAPHY
8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO

8.3 EUROPE

8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE

8.4 ASIA PACIFIC

8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC

8.5 MIDDLE EAST & AFRICA

8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA

8.6 SOUTH AMERICA

8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA

9 GLOBAL INTERVENTIONAL ONCOLOGY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES

10 COMPANY PROFILES

10.1 MEDTRONIC, INCORPORATED
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS

10.2 BOSTON SCIENTIFIC CORPORATION
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS

10.3 BECTON, DICKINSON, AND COMPANY
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS

10.4 TERUMO CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS

10.5 MERIT MEDICAL
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS

10.6 ANGIODYNAMICS
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS

10.7 JOHNSON & JOHNSON
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS

10.8 TELEFLEX INCORPORATED
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS

10.9 COOK GROUP
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS

10.10 HEALTHTRONICS, INCORPORATED
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS